22.05.2017 Views

Review of Pharmacology - 9E (2015)

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Cardiovascular System<br />

Contd...<br />

• Major adverse effect <strong>of</strong> these drugs is myopathy and hepatotoxicity. Chances <strong>of</strong><br />

myopathy increases if these are co-administered with fibrates (maximum with<br />

gemfibrozil) or niacin. Myopathy can proceed to rhabdomyolysis with resultant<br />

renal shutdown. Pravastatin remains confined to the liver and is safer in this regard.<br />

These agents should be avoided in pregnancy and lactation.<br />

• Statins are the first line drugs for type IIa, type IIb and secondary hyperlipoproteinemia<br />

(in these conditions, cholesterol level is raised more than TG).<br />

• In children with heterozygous familial hypercholesterolemia, pravastatin is<br />

approved for children ≥ 8 years whereas other statins are approved for children<br />

≥ 10 years. Pitavastatin has not been studied for this indication.<br />

INTESTINAL CHOLESTEROL ABSORPTION INHIBITOR<br />

Ezetimibe inhibits a transporter involved in intestinal absorption <strong>of</strong> cholesterol called NPC1L1.<br />

Due to decreased absorption, cholesterol content <strong>of</strong> the liver decreases and it responds by<br />

increasing LDL receptor synthesis. It can be used alone or combined with statins for type IIa<br />

and IIb hyperlipoproteinemia.<br />

BILE ACID BINDING RESINS<br />

These drugs bind to bile acids in the intestinal lumen and decrease its reabsorption (resulting in<br />

more excretion through faeces). Cholesterol pool <strong>of</strong> liver is depleted because it is utilized for<br />

the formation <strong>of</strong> bile acids. Liver acquires cholesterol from the plasma by increasing LDL<br />

receptors. Bile acids inhibit TG production in the liver and their deficiency results in elevation<br />

<strong>of</strong> TGs. Bile acid binding resins are used only for type IIa disorder (TGs are normal in this<br />

condition). Drugs in this group include cholestyramine, colestipol and colesevelam.<br />

Cholestyramine and colestipol are available as sachets. These are mixed with water, kept for<br />

some time (to increase the palatability) and then taken with meals. Colesevelam is available as<br />

a tablet and has better patient compliance. Major adverse effect <strong>of</strong> these drugs is constipation.<br />

FIBRIC ACID DERIVATIVES<br />

This group <strong>of</strong> drugs acts by activating LPL by activating a nuclear receptor, PPARα (peroxisome<br />

proliferator activated receptor alpha). Major effect <strong>of</strong> the fibrates is to reduce TG (contained<br />

in VLDL) and to increase HDL. Cl<strong>of</strong>ibrate is not used now because it resulted in increased<br />

mortality (due to malignancies and post cholecystectomy complications) and did not prevent<br />

fatal MI. Gemfibrozil, fen<strong>of</strong>ibrate and bezafibrate are currently available. Fen<strong>of</strong>ibrate is a prodrug<br />

with longest half life. It has maximum LDL cholesterol lowering action. Fibrates also reduce<br />

plasma fibrinogen level. Fibrates are the drugs <strong>of</strong> choice in hypertriglyceridemia (type III<br />

and IV) and can be used with other drugs in type IIb (fen<strong>of</strong>ibrate, as it has maximum LDL<br />

reducing action). Fen<strong>of</strong>ibrate is uricosuric and can be used in the setting <strong>of</strong> hyperuricemia.<br />

GI distress and elevation <strong>of</strong> aminotransferases are important adverse effects <strong>of</strong> fibric acid<br />

derivatives. Risk <strong>of</strong> myopathy is increased if these are used with statins except bezafibrate.<br />

NICOTINIC ACID<br />

Niacin (not nicotinamide) is an inexpensive drug (vitamin B 3<br />

) that produces decrease in<br />

LDL cholesterol and VLDL triglycerides along with increase in HDL cholesterol. It acts<br />

by inhibiting lipolysis in the adipose tissue. Among all hypolipidemic drugs, niacin has<br />

maximum HDL increasing property; therefore it is useful in patients having increased risk<br />

<strong>of</strong> CAD. Further, it can also decrease lipoprotein (a) and fibrinogen. It is useful for type IIb,<br />

III and IV disorders. Main compliance limiting feature is cutaneous flushing and pruritis.<br />

These symptoms are due to vasodilatory action <strong>of</strong> niacin through release <strong>of</strong> PGs and can<br />

be prevented by pretreatment with aspirin. To minimize the side effects, niacin should be<br />

started at low doses. Other important adverse effects are GI toxicity and hyperuricemia.<br />

Niacin can also lead to hepatotoxicity which is manifested by fall in both LDL as well HDL<br />

cholesterol.<br />

Pleotropic Effects <strong>of</strong> Statins<br />

• Antioxidant<br />

• Anti-inflammatory<br />

• Anti-proliferative<br />

All statins can be absorbed orally<br />

(maximum fluvastatin).<br />

Bile acids inhibit TG production<br />

in the liver and their deficiency<br />

results in elevation <strong>of</strong> TGs.<br />

N<br />

Mipomersen is an antisense oligonucleotide<br />

inhibitor <strong>of</strong> mRNA<br />

<strong>of</strong> apo B-100 synthesis. It is<br />

indicated as once weekly injection<br />

for treatment <strong>of</strong> homozygous<br />

familial hypercholestrolemia<br />

Fibrates are drugs <strong>of</strong> choice in<br />

hypertriglyceridemia (type III<br />

and IV)<br />

173<br />

General Cardiovascular <strong>Pharmacology</strong> System<br />

https://kat.cr/user/Blink99/

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!